Figure 4

Human rIL-2 transiently increases peripheral blood CD4⁺ and CD8⁺ Tregs in a dose-dependent manner . (A) Gating strategy for the identification of Treg cells. Cells were first gated on side and forward scatter parameters (gate R1) and further gated on CD4⁺ T cells (gate R2) to analyze CD25 and FoxP3 expression. CD4⁺FoxP3⁺CD25^high or CD8⁺FoxP3⁺CD25^high (R3) were then analyzed for CD127 expression. CD4⁺FoxP3⁺CD25^highCD127^low or CD8⁺FoxP3⁺CD25^highCD127^low were identified as CD4 or CD8 Tregs respectively. (B) Percentages and counts of peripheral blood CD4⁺CD25^high and CD8⁺CD25 ^high cells in IL-2-treated macaques (low dose, #056212, #056216 – high dose, #056230, #056238) at days 0, 7 and 45 after IL-2 treatment. (C) Percentages and counts of CD4 or CD8 Tregs in IL-2-treated macaques (low dose #056212, #056216 – high dose #056230, #056238) at day 0, 7 and 45 after IL-2 treatment.